Advanced in Progressive Supranuclear Palsy

Dr. David S. Russell

Neurology
60 Temple St, Suite 8b, 
New Haven, CT 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Progressive Supranuclear Palsy
60 Temple St, Suite 8b, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Russell is a Neurologist in New Haven, Connecticut. Dr. Russell is rated as an Advanced provider by MediFind in the treatment of Progressive Supranuclear Palsy. His top areas of expertise are Movement Disorders, Parkinson's Disease, Progressive Supranuclear Palsy Atypical, and Progressive Supranuclear Palsy.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 31 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 3 clinical trials in the study of Progressive Supranuclear Palsy.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO

Locations

60 Temple St, Suite 8b, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort
The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort
Enrollment Status: Recruiting
Publish Date: October 27, 2025
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
Plasma P-tau2017 and Quantitative Amyloid PET Imaging in a Cognitively Normal Population
Plasma P-tau2017 and Quantitative Amyloid PET Imaging in a Cognitively Normal Population
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Drug
Study Phase: Phase 1
Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy
Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: February 20, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ (PPMI Early Imaging)
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ (PPMI Early Imaging)
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2024
The Parkinson's Progression Markers Initiative (PPMI)
The Parkinson's Progression Markers Initiative (PPMI)
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: DaTscan
Study Phase: Phase 2
A Phase 2, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects
A Phase 2, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects
Enrollment Status: Unknown
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drug: 18F APN-1607
Study Phase: Phase 2
Assessment of Brain Tau Burden in Participants With Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging)
Assessment of Brain Tau Burden in Participants With Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging)
Enrollment Status: Completed
Publish Date: April 21, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Adaptive Design, Phase 1, Open-label Study to Investigate Receptor Occupancy in Brain After Single Oral Doses of LY3857210 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]-LY3818850 in Healthy Participants
An Adaptive Design, Phase 1, Open-label Study to Investigate Receptor Occupancy in Brain After Single Oral Doses of LY3857210 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]-LY3818850 in Healthy Participants
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Drug
Study Phase: Phase 1
The Dementia Symptom Management at Home Program: A Bundled Interprofessional Intervention to Improve Dementia Patient-Caregiver Dyad Quality of Care and Quality of Life Through Home Healthcare.
The Dementia Symptom Management at Home Program: A Bundled Interprofessional Intervention to Improve Dementia Patient-Caregiver Dyad Quality of Care and Quality of Life Through Home Healthcare.
Enrollment Status: Withdrawn
Publish Date: November 02, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 1 Proof of Principle Study to Evaluate the Occupancy of A2A Receptors Using PET Radiotracer [18F]MNI-444 & Repeated Dosing of Oral Caffeine in Participants Without Parkinson's Disease Who Carry Pathogenic Mutation in the LRRK2 Gene
A Phase 1 Proof of Principle Study to Evaluate the Occupancy of A2A Receptors Using PET Radiotracer [18F]MNI-444 & Repeated Dosing of Oral Caffeine in Participants Without Parkinson's Disease Who Carry Pathogenic Mutation in the LRRK2 Gene
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Multiple Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LY3316612 in Healthy Subjects
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Multiple Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LY3316612 in Healthy Subjects
Enrollment Status: Completed
Publish Date: November 04, 2020
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 1
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Single Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LSN3316612 in Healthy Subjects
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Single Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LSN3316612 in Healthy Subjects
Enrollment Status: Completed
Publish Date: April 22, 2020
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 1
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).
Enrollment Status: Completed
Publish Date: April 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Assessment of the Biodistribution and Safety of [18F]MNI-1054 in Healthy Subjects
Assessment of the Biodistribution and Safety of [18F]MNI-1054 in Healthy Subjects
Enrollment Status: Completed
Publish Date: May 23, 2019
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-1054 as a Marker for LSD1 in Healthy Subjects
An Open-label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-1054 as a Marker for LSD1 in Healthy Subjects
Enrollment Status: Completed
Publish Date: May 23, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
An Open-Label Study To Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) With Ligand [18F]MNI-968 in Healthy Male Subjects
An Open-Label Study To Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) With Ligand [18F]MNI-968 in Healthy Male Subjects
Enrollment Status: Completed
Publish Date: April 22, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
Enrollment Status: Completed
Publish Date: October 22, 2018
Intervention Type: Drug
Study Phase: Phase 1
Assessment of the Biodistribution and Safety of [18F]MNI-968 (Aka PF-06730110) in Healthy Subjects
Assessment of the Biodistribution and Safety of [18F]MNI-968 (Aka PF-06730110) in Healthy Subjects
Enrollment Status: Completed
Publish Date: March 06, 2018
Intervention Type: Drug
Study Phase: Phase 1
An Open Label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
An Open Label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
Enrollment Status: Completed
Publish Date: March 06, 2018
Intervention Type: Drug
Study Phase: Early Phase 1
Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers
Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers
Enrollment Status: Completed
Publish Date: October 06, 2017
Intervention Type: Drug
Study Phase: Early Phase 1
Systemic Synuclein Sampling Study (S4)
Systemic Synuclein Sampling Study (S4)
Enrollment Status: Completed
Publish Date: August 17, 2017
Intervention Type: Drug, Procedure
Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions
Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions
Enrollment Status: Completed
Publish Date: January 06, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 30 Less Clinical Trials

35 Total Publications

Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.
Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: January 22, 2025
Similar Doctors
Distinguished in Progressive Supranuclear Palsy
Dr. John P. Seibyl
Neurology
Distinguished in Progressive Supranuclear Palsy
Dr. John P. Seibyl
Neurology
60 Temple St, Suite 8b, 
New Haven, CT 
 (0.1 miles away)
203-401-4300
Languages Spoken:
English

John Seibyl is a Neurologist in New Haven, Connecticut. Dr. Seibyl is rated as a Distinguished provider by MediFind in the treatment of Progressive Supranuclear Palsy. His top areas of expertise are Movement Disorders, Parkinson's Disease, Alzheimer's Disease, and Dementia.

Advanced in Progressive Supranuclear Palsy
Dr. Veronica E. Santini
Neurology
Advanced in Progressive Supranuclear Palsy
Dr. Veronica E. Santini
Neurology

Yale University

20 York St, 
New Haven, CT 
 (0.4 miles away)
203-688-4242
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Veronica Santini is a Neurologist in New Haven, Connecticut. Dr. Santini has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Progressive Supranuclear Palsy. Her top areas of expertise are Movement Disorders, Parkinson's Disease, Drug Induced Dyskinesia, Thalamotomy, and Sacral Nerve Stimulation.

Distinguished in Progressive Supranuclear Palsy
Dr. Guy J. Schwartz
Neurology
Distinguished in Progressive Supranuclear Palsy
Dr. Guy J. Schwartz
Neurology

Neurology Associates Of Stony Brook, University Faculty Practice Corpo

Lauterbur Dr, 
Stony Brook, NY 
 (29.1 miles away)
631-638-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Guy Schwartz is a Neurologist in Stony Brook, New York. Dr. Schwartz is rated as a Distinguished provider by MediFind in the treatment of Progressive Supranuclear Palsy. His top areas of expertise are Movement Disorders, Parkinson's Disease, Supranuclear Ophthalmoplegia, and Progressive Supranuclear Palsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Russell's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 7 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile